About HLRI
The Heart and Lung Research Institute (HLRI) is a joint venture between Royal Papworth Hospital and The University of Cambridge. It will draw together the NHS, academia, industry and charity to create a world-leading research environment to deliver high-impact research tackling global cardiovascular and respiratory diseases.
HLRI is being built next to Royal Papworth Hospital - ©Keith Heppell
The researchers based inside HLRI will focus on prevention, early diagnosis and treatment of cardiovascular and lung disease, by creating, testing and delivering new treatments to tackle the biggest causes of premature death in the world all on one site.
Combining the world-leading science, research and clinical excellence, it has set an ambitious five year target to demonstrate proof-of-concept for at least 10 new drugs or diagnostic approaches in heart and lung diseases.
Together we can transform the future for those with heart and lung disease
The HLRI is situated next to Royal Papworth Hospital on the Cambridge Biomedical Campus, the largest biotech cluster outside the United States. It is home to more than 380 scientists and medical professionals with state-of-the-art laboratories in genomics, population sciences, research into cellular mechanisms of disease and translational science. It will also include a special 10 bed facility where the first-in-patient studies of new treatments can be conducted.
Royal Papworth Hospital Charity is contributing over £5 million to support the build of the HLRI to ensure our patients have access to the world's best treatments.
Find out more about Royal Papworth Charity's appeal
Photos
Groundwork on HLRI began back in October 2019 with construction starting in January 2020. The building was handed over by constructors sdc in spring 2022.
March 2022
The HLRI (right) is situated next to Royal Papworth Hospital on the Cambridge Biomedical Campus, joined together with an underground tunnel.
December 2021
This view does not work with Internet Explorer 11. Please use either Chrome, Firefox or Microsoft Edge.